Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

MAVORIC Investigators, Bryone Jean Kuss

Research output: Contribution to journalArticlepeer-review

221 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences